KR102346913B1 - 갈렉틴과 관련된 질환의 예방 및 치료를 위한 셀레노갈락토시드 화합물 및 이의 용도 - Google Patents

갈렉틴과 관련된 질환의 예방 및 치료를 위한 셀레노갈락토시드 화합물 및 이의 용도 Download PDF

Info

Publication number
KR102346913B1
KR102346913B1 KR1020187028691A KR20187028691A KR102346913B1 KR 102346913 B1 KR102346913 B1 KR 102346913B1 KR 1020187028691 A KR1020187028691 A KR 1020187028691A KR 20187028691 A KR20187028691 A KR 20187028691A KR 102346913 B1 KR102346913 B1 KR 102346913B1
Authority
KR
South Korea
Prior art keywords
group
substituted
heteroaryl
naphthyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187028691A
Other languages
English (en)
Korean (ko)
Other versions
KR20180128419A (ko
Inventor
샤론 쉐터
엘리제 조머
피터 쥐 트래버
라파엘 니어
조셉 엠 존슨
라이언 조지
Original Assignee
갈랙틴 사이언시즈, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈랙틴 사이언시즈, 엘엘씨 filed Critical 갈랙틴 사이언시즈, 엘엘씨
Publication of KR20180128419A publication Critical patent/KR20180128419A/ko
Application granted granted Critical
Publication of KR102346913B1 publication Critical patent/KR102346913B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020187028691A 2016-03-04 2017-03-03 갈렉틴과 관련된 질환의 예방 및 치료를 위한 셀레노갈락토시드 화합물 및 이의 용도 Active KR102346913B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662303872P 2016-03-04 2016-03-04
US62/303,872 2016-03-04
PCT/US2017/020658 WO2017152048A1 (en) 2016-03-04 2017-03-03 Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof

Publications (2)

Publication Number Publication Date
KR20180128419A KR20180128419A (ko) 2018-12-03
KR102346913B1 true KR102346913B1 (ko) 2022-01-04

Family

ID=59744474

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028691A Active KR102346913B1 (ko) 2016-03-04 2017-03-03 갈렉틴과 관련된 질환의 예방 및 치료를 위한 셀레노갈락토시드 화합물 및 이의 용도

Country Status (11)

Country Link
US (2) US20190367552A1 (enExample)
EP (1) EP3423461A4 (enExample)
JP (1) JP7086008B2 (enExample)
KR (1) KR102346913B1 (enExample)
CN (1) CN109071585B (enExample)
AU (1) AU2017228365B2 (enExample)
CA (1) CA3016343C (enExample)
IL (2) IL261431B (enExample)
MX (1) MX394409B (enExample)
WO (1) WO2017152048A1 (enExample)
ZA (1) ZA201805900B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102626669B1 (ko) * 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
JP2021501180A (ja) * 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用
KR20210124308A (ko) * 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
US12404295B2 (en) * 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
CN113476442A (zh) * 2021-07-28 2021-10-08 上海交通大学医学院附属第九人民医院 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用
KR102990426B1 (ko) 2022-04-06 2026-07-13 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 폐섬유증 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
WO2015155207A1 (en) 2014-04-08 2015-10-15 Galecto Biotech Ab Galactoside inhibitors for the treatment of alpha-synucleinopthies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
AU2007319806A1 (en) * 2006-11-15 2008-05-22 The Brigham And Women's Hospital, Inc. Therapeutic uses of TIM-3 modulators
ES2652488T3 (es) * 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
CA2794066C (en) * 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
CN104245717B (zh) * 2011-12-28 2017-10-24 卡莱克汀医疗有限公司 用于治疗人类疾病的新型糖类药物的组合物
EP2620443A1 (en) * 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
IN2015DN02573A (enExample) * 2012-10-31 2015-09-11 Galecto Biotech Ab
EP3125908A4 (en) * 2014-03-10 2017-11-15 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
WO2015155207A1 (en) 2014-04-08 2015-10-15 Galecto Biotech Ab Galactoside inhibitors for the treatment of alpha-synucleinopthies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.A.Kumar et al., Carbohydrate Research, Vol.360 (2012) pp.8-18*
B.M.Swarts et al., Adv. Carbohydra. Chem Biochem., Vol.67 (2012) pp.1-113
S.Andre et al., Bioorganic Medicinal Chem. Letters, Vol.25 (2015) pp.931-935*

Also Published As

Publication number Publication date
US20190367552A1 (en) 2019-12-05
BR112018067693A2 (pt) 2019-01-08
CN109071585A (zh) 2018-12-21
CA3016343A1 (en) 2017-09-08
MX394409B (es) 2025-03-24
JP2019507194A (ja) 2019-03-14
EP3423461A4 (en) 2020-03-25
WO2017152048A1 (en) 2017-09-08
KR20180128419A (ko) 2018-12-03
CA3016343C (en) 2024-03-26
MX2018010683A (es) 2019-05-27
JP7086008B2 (ja) 2022-06-17
AU2017228365B2 (en) 2021-05-27
ZA201805900B (en) 2019-07-31
AU2017228365A1 (en) 2018-09-27
IL281585B (en) 2022-04-01
US20230127345A1 (en) 2023-04-27
IL281585A (en) 2021-05-31
EP3423461A1 (en) 2019-01-09
CN109071585B (zh) 2022-08-16
IL261431A (en) 2018-10-31
IL261431B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
KR102626669B1 (ko) 질환의 예방 및 치료를 위한 화합물 및 이의 용도
KR20200081443A (ko) 전신성 인슐린 저항성 질환의 치료를 위한 셀레노갈락토사이드 화합물 및 이의 용도
US20230127345A1 (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
KR20200015528A (ko) 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도
KR102692840B1 (ko) 의학적 장애의 예방 및 치료를 위한 화합물 및 이의 용도
JP2020122021A (ja) ガレクチンの新規なガラクトシド阻害剤
BR112018067693B1 (pt) Selenogalactosídeos, seus usos, e composição

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5